Hazem Abdulelah

Consultant Internal Medicine and Medical Oncologist

Education and Training

M.B./B.S. Sind Medical College, University of Karachi, Pakistan
1993-1997 Residency, Internal Medicine, Islamic Hospital, Jordan
2005-2008 Fellowship in Medical Oncology, King Hussein Cancer Center (KHCC), Jordan

Board Certifications

Jordanian Board of Medical Oncology
Jordanian Board of Internal Medicine

Experience

2008-Present Consultant, Department of Hematology & Medical Oncology, KHCC, Jordan
2005-2008 Fellowship, Department of Hematology & Medical Oncology, KHCC, Jordan
2003-2005 Staff Physician, Department of Internal Medicine/ICU, King Abdulaziz National Guard Hospital, Kingdom of Saudi Arabia
1999-2003 Registrar, Department of Internal Medicine/ICU, King Abdulaziz University Hospital, Kingdom of Saudi Arabia
1997-1999 Registrar, Internal Medicine, Islamic Hospital, Jordan
1997 Registrar, Internal Medicine, Al-Khaldi Hospital & Medical Center, Jordan
1993-1997 Resident, Internal Medicine, Islamic Hospital, Jordan
1990-1992 Intern, Sind Medical College, Jinnah Postgraduate Medical Center, Pakistan

Professional Memberships

Jordanian Medical Association
Saudi Medical Association for Medical Specialties
American Society of Clinical Oncology
European Society for Medical Oncology
Jordanian Society of Hematology
Jordanian Society of Oncology
Jordan Pain Society

Publications

Abdel-Razeq, Hikmat, et al. "The impact of recently published negative erythropoiesis-stimulating agent studies on the clinical management of cancer-related anemia at a single center." Hematology/oncology and stem cell therapy 3.2 (2010): 78-83.
Abdel-Razeq, Hikmat, et al. "Inferior vena cava filters in cancer patients: to filter or not to filter." Therapeutics and Clinical Risk Management 7 (2011): 99.
Abdel-Razeq, Hikmat, et al. "Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study." Drug design, development and therapy 7 (2013): 939.
Khater, Wejdan A., et al. "The practice of withholding and withdrawing life-support measures among patients with cancer in Jordan." International journal of palliative nursing 17.9 (2011): 440-445.
Abdel-Razeq, Hikmat, et al. "Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study." Drug design, development and therapy 7 (2013): 939.
Abdel-Razeq, Hikmat, et al. "From clinical trials to clinical practice: outcome of NSABP-B27 neoadjuvant chemotherapy regimen for high-risk early-stage breast cancer." Breast cancer research and treatment 165.3 (2017): 771-777.
Fasching, Peter A., et al. "Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3." (2016): TPS624-TPS624.
Abdel-Razeq, Hikmat, et al. "Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!." Thrombosis journal 16.1 (2018): 2.
Vitamin D deficiency in women with newly-diagnosed breast cancer in Jordan; Prevalence, Clinical and Pathological correlations.
The validation of Gail Model in Jordanian women with breast cancer.
Retrospective analysis of clinicopathological features of patient with multiple primary malignancies diagnosed at king Hussein Cancer Center from 2003 to 2009.
TRIple Negative Breast Cancer PrOspective Registry in Eastern Europe, MiddLe East, and Africa Protocol 7167.
Four cycles of Adriamycin plus Cyclophosphamide (AC) followed by four cycles of Docetaxel (NSABP-B27) with concomitant Trastuzumab as neoadjuvant therapy for high risk, early-stage, HER2-positive breast cancer patients." has been accepted for publication in "OncoTargets and Therapy".

Academic Classification

Assistant Member

Contact Information

Email Address: habdulelah@khcc.jo
Phone Number: 96265300460-1037